Table 3 Characteristics of venous thromboembolism in COVID-19 patients
Variables | All patients N = 143 (%) | Survival N = 112 (%) | Death N = 31 (%) |
|---|---|---|---|
Biomarkers | |||
D-dimer (mcg/mL), median (IQR) | 7794 (3320 – 17,460) | 7700 (3200 – 16,125) | 8897 (4352 – 33,175) |
Hs-cTn (ng/mL), median (IQR) | 57 (14.5 – 191) | - | - |
Ferritin (ng/mL), median (IQR) | 765 (402 – 1456) | - | - |
Imaging studies | |||
Right ventricular dysfunction (TTE) | 56 (39.2) | 35 (31.3) | 21 (67.8) |
CTPA | |||
Saddle PE | 10 (7) | 9 (8) | 1 (3.2) |
Main branches | 38 (26.6) | 34 (30.4) | 4 (12.9) |
Lobar branches | 22 (15.4) | 19 (17) | 3 (9.7) |
Segmental branches | 27 (18.9) | 23 (20.5) | 4 (12.9) |
Subsegmental branches | 7 (4.9) | 7 (6.3) | 0 (0) |
Doppler US and DVT | 30 (20.9) | 25 (22.3) | 5 (16.1) |
COVID-19 severity | |||
Asymptomatic | 14 (9.8) | 12 (10.7) | 2 (6.5) |
Mild symptoms | 9 (6.3) | 8 (7.1) | 1 (3.2) |
Fever | 27 (18.9) | 23 (20.5) | 4 (12.9) |
Pneumonia | 62 (43.4) | 55 (49.1) | 7 (22.6) |
ARDS | 58 (40.6) | 37 (33) | 21 (67.7) |
Mechanical ventilation | 56 (39.2) | 32 (28.6) | 24 (77.4) |
ICU | 69 (48.3) | 40 (35.7) | 29 (93.5) |
Laboratories | |||
Leukocytes (10(9) u/L), median (IQR) | 11.9 (9.7 – 15.4) | 11.4 (9.4 – 13.6) | 13.8 (10.8 – 20.3) |
Lymphocytes (10(3) u/L), mean ± SD | 928.3 ± 448.5 | 994.1 ± 461.5 | 731.1 ± 360.1 |
Platelets (10(3) u/L), mean ± SD | 246.8 ± 129.8 | 254.4 ± 122.9 | 233.7 ± 143.7 |
LDH (U/L), median (IQR) | 575 (391.8 – 739.3) | - | - |
CRP (mg/L), median (IQR) | 113.1 (50.6 – 222.5) | 92.9 (50 – 160) | 244.9 (154 – 345.4) |
RT-PCR SARS-CoV-2 (+) | 142 (99.3) | 111 (99.1) | 31 (100) |
Imagen studies | |||
Bilateral infiltrates (chest X-ray) | 49 (34.3) | 37 (33) | 12 (38.7) |
CT with CO-RADS 5 | 49 (34.3) | 43 (38.4) | 6 (19.4) |
Previous anticoagulation treatment | |||
Direct-acting oral anticoagulants | 1 (0.7) | 1 (0.9) | 0 (0) |
Vitamin K antagonists | 2 (1.4) | 1 (0.9) | 1 (3.2) |